Tomomi M Yamamoto

10PUBLICATIONS
54CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsChemotherapyPredictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (10)

|Aug 19, 2026
Inhibiting CXCR2 remodels the tumor microenvironment and blunts tumor progression and dissemination of high-grade serous carcinoma.

|Jan 24, 2026
Chromobox 2 Inhibition: A Novel Activity of Alisertib, an Aurora A Kinase Inhibitor.

Tomomi M Yamamoto, Ritsuko Iwanaga, Elizabeth R Woodruff

|Dec 04, 2025
SM08502-Mediated β-Catenin Repression Synergizes with Olaparib to Inhibit Tumor Progression.

Bradley R Corr, Elizabeth R Woodruff, Tomomi M Yamamoto

|Dec 16, 2024
Cannabidiol promotes apoptosis and downregulation of oncogenic factors.

Ashley Greenwood, Tomomi M Yamamoto, Molishree Joshi

|Aug 13, 2024
EHMT1/2 Inhibition Promotes Regression of Therapy-Resistant Ovarian Cancer Tumors in a CD8 T-cell-Dependent Manner.

Lily L Nguyen, Zachary L Watson, Raquel Ortega

|Jul 10, 2024
Tumor-Intrinsic Activity of Chromobox 2 Remodels the Tumor Microenvironment in High-grade Serous Carcinoma.

Ritsuko Iwanaga, Tomomi M Yamamoto, Karina Gomez

Pageof 2

Frequent Collaborators

10 joint publications

Benjamin G Bitler

8 joint publications

Elizabeth R Woodruff

6 joint publications

Ritsuko Iwanaga

6 joint publications

Lily L Nguyen